Alqdwah-Fattouh Rasha, Rodríguez-Martín Sara, de Abajo Francisco J, González-Bermejo Diana, Gil Miguel, García-Lledó Alberto, Bolúmar Francisco
Unit of Epidemiology and Public Health. School of Medicine, University of Alcalá, Madrid, Spain.
Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
Br J Clin Pharmacol. 2020 Oct;86(10):2040-2050. doi: 10.1111/bcp.14299. Epub 2020 May 9.
The primary objective of this study was to investigate the association between antidepressants use and the risk of acute myocardial infarction (AMI).
We conducted a nested case-control study using a primary care database over the period 2002-2015. From a cohort of patients aged 40-99 years, we identified incident AMI cases and randomly selected 5 controls per case, matched to cases for exact age, sex and index date. Exposure to antidepressants were categorised as current, recent, past and nonusers. Adjusted odds ratio (AOR) and 95% confidence interval (CI) were computed using conditional logistic regression to assess the association between the current use of different antidepressants subgroups and AMI as compared to nonuse. Dose and duration effects were explored.
Totals of 24 155 incident AMI cases and 120 775 controls were included. The current use of antidepressants as a group was associated with a reduced risk (AOR = 0.86; 95% CI: 0.81-0.91), but mainly driven by selective serotonin reuptake inhibitors (AOR = 0.86; 95% CI:0.81-0.93). A reduced risk was also observed with trazodone (AOR = 0.76;95% CI: 0.64-0.91), and clomipramine (AOR = 0.62; 95% CI: 0.40-0.96), whereas no significant effect was observed with other antidepressants. A duration-dependent effect was suggested for selective serotonin reuptake inhibitors, trazodone and clomipramine, while there was no clear dose-dependency.
This study suggests that current use of antidepressants interfering selectively with the reuptake of serotonin, and those antagonizing the 5-HT receptor, are associated with a decrease in AMI risk and should be the antidepressants of choice in patients at cardiovascular risk.
本研究的主要目的是调查使用抗抑郁药与急性心肌梗死(AMI)风险之间的关联。
我们利用一个初级保健数据库在2002年至2015年期间进行了一项巢式病例对照研究。从40至99岁的患者队列中,我们确定了急性心肌梗死的发病病例,并为每个病例随机选取5名对照,对照与病例在确切年龄、性别和索引日期上相匹配。抗抑郁药的使用情况分为当前使用、近期使用、过去使用和未使用者。使用条件逻辑回归计算调整后的比值比(AOR)和95%置信区间(CI),以评估不同抗抑郁药亚组当前使用情况与未使用相比与急性心肌梗死之间的关联。探讨了剂量和疗程效应。
共纳入24155例急性心肌梗死发病病例和120775名对照。作为一个整体,当前使用抗抑郁药与风险降低相关(AOR = 0.86;95% CI:0.81 - 0.91),但主要由选择性5-羟色胺再摄取抑制剂驱动(AOR = 0.86;95% CI:0.81 - 0.93)。曲唑酮(AOR = 0.76;95% CI:0.64 - 0.91)和氯米帕明(AOR = 0.62;95% CI:0.40 - 0.96)也观察到风险降低,而其他抗抑郁药未观察到显著效应。对于选择性5-羟色胺再摄取抑制剂、曲唑酮和氯米帕明,提示存在疗程依赖性效应,而没有明确的剂量依赖性。
本研究表明,当前使用选择性干扰5-羟色胺再摄取的抗抑郁药以及拮抗5-羟色胺受体的抗抑郁药与急性心肌梗死风险降低相关,应是心血管风险患者的首选抗抑郁药。